Payment overview · 2025
General Payments
$240.44
8 reported records · 6 companies
Healthcare provider profile · identity verified
Larisa Golub, MD
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · FLEMINGTON, NJ · NPI 1710956586
Verified facts
What the public records show
CMS Open Payments records show Larisa Golub, MD received $240.44 in general payments during 2025 across 8 reported records.
Lilly USA, LLC accounted for 61.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $147.76 | 61.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.47 | 8.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.00 | 7.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.37 | 7.6% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.35 | 7.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.49 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.44 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $147.76 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 440 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 426 | 70 |
| Eliquis | Apixaban | 325 | 33 |
| Furosemide | Furosemide | 324 | 47 |
| Mirtazapine | Mirtazapine | 268 | 40 |
| Divalproex Sodium | Divalproex Sodium | 266 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 47 |
| Gabapentin | Gabapentin | 234 | 40 |
| Potassium Chloride | Potassium Chloride | 216 | 38 |
| Xarelto | Rivaroxaban | 171 | 11 |
| Donepezil Hcl | Donepezil Hcl | 168 | 25 |
| Carvedilol | Carvedilol | 147 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 145 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 27 |
| Buspirone Hcl | Buspirone Hcl | 142 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 26 |
| Famotidine | Famotidine | 142 | 17 |
| Trazodone Hcl | Trazodone Hcl | 138 | 23 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 132 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 25 |
| Lisinopril | Lisinopril | 112 | 13 |
| Memantine Hcl | Memantine Hcl | 102 | 19 |
| Omeprazole | Omeprazole | 97 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 17 |
| Allopurinol | Allopurinol | 92 | 11 |
| Januvia | Sitagliptin Phosphate | 92 | suppressed |
| Olanzapine | Olanzapine | 85 | suppressed |
| Baclofen | Baclofen | 84 | 11 |
| Levetiracetam | Levetiracetam | 84 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 14 |
| Metformin Hcl | Metformin Hcl | 81 | 14 |
| Sertraline Hcl | Sertraline Hcl | 81 | 15 |
| Losartan Potassium | Losartan Potassium | 80 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 78 | 16 |
| Risperidone | Risperidone | 76 | suppressed |
| Trulicity | Dulaglutide | 72 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 68 | 34 |
| Memantine Hcl Er | Memantine Hcl | 65 | 16 |
| Spironolactone | Spironolactone | 65 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 64 | suppressed |
| Simvastatin | Simvastatin | 64 | suppressed |
| Finasteride | Finasteride | 60 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 14 |
| Torsemide | Torsemide | 59 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 58 | 58 |
| Benztropine Mesylate | Benztropine Mesylate | 58 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 58 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | suppressed |
| Fentanyl | Fentanyl | 51 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 49 | suppressed |
| Bumetanide | Bumetanide | 49 | suppressed |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 13 |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Procrit | Epoetin Alfa | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Timolol Maleate | Timolol Maleate | 36 | suppressed |
| Creon | Lipase/Protease/Amylase | 35 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 33 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 33 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Mupirocin | Mupirocin | 30 | 13 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | suppressed |
| Prednisone | Prednisone | 28 | 14 |
| Clonazepam | Clonazepam | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 20 |
| Digoxin | Digoxin | 26 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 26 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Pulmicort Flexhaler | Budesonide | 24 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 14 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Famciclovir | Famciclovir | 21 | suppressed |
| Restasis | Cyclosporine | 21 | suppressed |
| Venlafaxine Besylate Er | Venlafaxine Besylate | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | 11 |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | 11 |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Drizalma Sprinkle | Duloxetine Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.44 · 8 records | Lilly USA, LLC | AUSTEDO XR, KISUNLA, LEQVIO, Leqembi, NUPLAZID, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error